Inmune Bio, Inc.

INMB

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001711754

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $32.4M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data, degenerate inputs; fortress... not computable: short runway, distress
Inputs computable	6 of 14
Graded from	filings received through Mar 30, 2026 207 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$1.55 2026-10-22; market equity $43.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 30, 2026

Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction Program: CORDStrom? for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) using CORDStrom, our proprietary, pooled, human umbilical cord-derived mesenchymal stromal cell platform. RDEB is a devastating pediatric orphan disease caused by mutations in the COL7A1 gene.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 6.5						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

required facts have no common fiscal period end						
Accruals ratio	(64.9%)	(6.6%)	6.5	812	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 63.8						
Twelve-month failure probability	not computable	0.06%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(23.76)	(0.30)	76.3	757	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
required facts have no common fiscal period end						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31						
Current ratio	3.55x	2.96x	51.3	840	2025-12-31	
Growth and financing, sleeve percentile 81.1						
Revenue growth, three-year compound	(48.9%)	10.1%	95.6	414	2025-12-31	
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 1						
Reinvestment rate	not computable	37.1%				
required facts have no common fiscal period end						
Asset growth, three years	(26.6%)	2.1%	90.5	705	2025-12-31	
Net share issuance, one year	15.9%	2.4%	57.1	633	2026-03-30	

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor
Fortress balance sheet	cash minus debt is 5,922,000 USD; Altman Z is not used

What the price implies

at the 2026-10-22 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	11.1%	8.0%	52
Distance from 52-week high	(38.6%)	(29.6%)	37
EBIT to enterprise value	(143.6%)	(1.5%)	4
Free cash flow yield	(55.3%)	(0.9%)	11
Book value to price	0.48	0.27	69
Sales to price	0.00	0.30	3
Composite equity issuance, five years	62.0%	20.5%	69
Relative strength against the sector, log excess return	(0.11)	(0.13)	52

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	78 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$581,727

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$45.9M	2025-12-31	2026-03-30	10-K	26-036370
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$22.6M	2025-12-31	2026-03-30	10-K	26-036370
3	assets	us-gaap:Assets	$32.4M	2025-12-31	2026-03-30	10-K	26-036370
4	assets	us-gaap:Assets	$39.6M	2024-12-31	2026-03-30	10-K	26-036370
5	current assets	us-gaap:AssetsCurrent	$29.9M	2025-12-31	2026-03-30	10-K	26-036370
6	current liabilities	us-gaap:LiabilitiesCurrent	$8.4M	2025-12-31	2026-03-30	10-K	26-036370
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$209.0M	2025-12-31	2026-03-30	10-K	26-036370
8	operating income	us-gaap:OperatingIncomeLoss	-$47.4M	2025-12-31	2026-03-30	10-K	26-036370
9	book equity	us-gaap:StockholdersEquity	$23.5M	2025-12-31	2026-03-30	10-K	26-036370
10	liabilities	us-gaap:Liabilities	$8.8M	2025-12-31	2026-03-30	10-K	26-036370
11	operating income	us-gaap:OperatingIncomeLoss	-$42.6M	2024-12-31	2026-03-30	10-K	26-036370
12	interest expense	us-gaap:InterestExpense	$789,000	2024-12-31	2025-03-27	10-K	25-003354
13	revenue	us-gaap:Revenues	$50,000	2025-12-31	2026-03-30	10-K	26-036370
14	revenue	us-gaap:Revenues	$14,000	2024-12-31	2026-03-30	10-K	26-036370
15	revenue	us-gaap:Revenues	$155,000	2023-12-31	2025-03-27	10-K	25-003354
16	revenue	us-gaap:Revenues	$374,000	2022-12-31	2024-03-28	10-K	24-027206
17	assets	us-gaap:Assets	$57.0M	2023-12-31	2025-03-27	10-K	25-003354
18	assets	us-gaap:Assets	$81.8M	2022-12-31	2024-03-28	10-K	24-027206
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	26,585,258	2026-03-30	2026-03-30	10-K	26-036370
20	shares outstanding	dei:EntityCommonStockSharesOutstanding	22,930,311	2025-03-27	2025-03-27	10-K	25-003354

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.